CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions

Overview of attention for article published in JCO Precision Oncology, December 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 2 news outlets
twitter: 33 X users

bluesky: 1 Bluesky user
podcasts: 1 podcast

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 1 Bluesky post from an account with 66 followers.

Patil et al’s phase II study of seribantumab in tumors harboring NRG1 fusions supports the anti-tumor activity and safety of seribantumab in patients with advanced solid tumors harboring NRG1 fusions. Read the full article. ascopubs.org/doi/abs/10.1...

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.